IMV Inc., a clinical-stage immuno-oncology company, together with its subsidiaries, develops products based on its platform and products with a primary focus on T cell activating therapies for cancer. The company's DepoVax platform is a patented formulation that provides controlled and prolonged exposure of antigens and adjuvant to the immune system. It has two T cell activation therapies for cancer through Phase I human clinical trial and is conducting a Phase Ib study with Incyte Corporation for lead cancer therapy; and DPX-Survivac, as a combination therapy for ovarian cancer. The company is also conducting a Phase II study for DPX-Survivac in ovarian and lymphoma. In addition, it is developing DPX-RSV, a vaccine candidate, which has completed a Phase I clinical trial for respiratory syncytial virus, as well as has clinical projects to assess the DepoVax to address malaria and the Zika virus; DPX-E7 an investigational immunotherapy that targets a viral protein in human papillomavirus (HPV) known as E7. The company has research collaborations with companies and research organizations, including Merck, Incyte Corporation, and Leidos Inc, as well as with Zoetis. The company was formerly known as Immunovaccine Inc. and changed its name to IMV Inc. in May 2018. IMV Inc. was founded in 2000 and is based in Dartmouth, Canada.
Industry, Sector and Symbol
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone+1-902-4921819
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesC$82,000.00
Profitability
Miscellaneous
Employees51
Next Earnings Date5/13/2019 (Estimated)
OptionableNot Optionable
IMV (TSE:IMV) Frequently Asked Questions
What is IMV's stock symbol?
IMV trades on the Toronto Stock Exchange (TSX) under the ticker symbol "IMV."
How were IMV's earnings last quarter?
Imv Inc (TSE:IMV) issued its quarterly earnings data on Thursday, March, 21st. The company reported ($0.17) EPS for the quarter, missing analysts' consensus estimates of ($0.09) by $0.08. The business earned $0.13 million during the quarter. View IMV's Earnings History.
When is IMV's next earnings date?
What price target have analysts set for IMV?
4 brokerages have issued 1-year price objectives for IMV's stock. Their forecasts range from C$10.40 to C$10.50. On average, they anticipate IMV's stock price to reach C$10.45 in the next year. This suggests a possible upside of 130.7% from the stock's current price. View Analyst Price Targets for IMV.
What is the consensus analysts' recommendation for IMV?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IMV in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for IMV.
Has IMV been receiving favorable news coverage?
Press coverage about IMV stock has been trending positive on Saturday, according to InfoTrie Sentiment Analysis. The research group identifies positive and negative news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. IMV earned a coverage optimism score of 2.6 on InfoTrie's scale. They also gave news articles about the company a news buzz of 3.0 out of 10, meaning that recent news coverage is unlikely to have an effect on the stock's share price in the next several days.
Who are some of IMV's key competitors?
Some companies that are related to IMV include Mesoblast (MSB), Resverlogix (RVX), Polynovo (PNV), Theratechnologies (TH), Emerald Health Therapeutics (EMH), Starpharma (SPL), Biotest (BIO), Oxford BioMedica (OXB), Neptune Wellness Solutions (NEPT), Senesco Technologies (ELOX), Kodiak Sciences (KOD), Enochian Biosciences (ENOB), Horizon Discovery Group (HZD), Monash IVF Group (MVF) and Emblem (EMC).
What other stocks do shareholders of IMV own?
Based on aggregate information from My MarketBeat watchlists, some companies that other IMV investors own include International Road Dynamics (IRD), Cronos Group (MJN), Village Farms International (VFF), Aurora Cannabis (ACB), Bombardier, Inc. Class B (BBD.B), ReNeuron Group (RENE), Aphria (APHA), Medical Facilities (DR), MedReleaf (LEAF) and Trevali Mining (TV).
Who are IMV's key executives?
IMV's management team includes the folowing people:
- Mr. Frederic Ors, Pres, CEO & Director (Age 45)
- Mr. Pierre Labbé C.A., C.P.A., CPA, CA, ICD, Chief Financial Officer (Age 54)
- Dr. Gabriela Nicola Rosu M.D., Chief Medical Officer
- Mr. Marc Jasmin CPA, CMA, Sr. Director of Investor Relations & Communications
- Mr. Joseph Sullivan, Sr. VP of Bus. Devel.
How do I buy shares of IMV?
Shares of IMV and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.
What is IMV's stock price today?
One share of IMV stock can currently be purchased for approximately C$4.53.
How big of a company is IMV?
IMV has a market capitalization of C$229.20 million and generates C$82,000.00 in revenue each year. IMV employs 51 workers across the globe.
What is IMV's official website?
How can I contact IMV?
IMV's mailing address is 1344 Summer Street, Suite 412, HALIFAX, NS B3H 0A8, Canada. The company can be reached via phone at +1-902-4921819.
MarketBeat Community Rating for IMV (TSE IMV)
MarketBeat's community ratings are surveys of what our community members think about IMV and other stocks. Vote "Outperform" if you believe IMV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IMV will underperform the S&P 500 over the long term. You may vote once every thirty days.
